| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.7 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
| mRNA | JQ12 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | 0.046 | 0.7 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |